Immunocytoma: A retrospective analysis from St Bartholomew's Hospital - 1972 to 1996

D. Papamichael, A. J. Norton, James M Foran, C. Mulatero, J. Mathews, J. A L Amess, M. Bradburn, T. A. Lister, A. Z S Rohatiner

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: To analyze the presentation features and outcome for patients with immunocytoma (IMC) managed at St Bartholomew's Hospital (SBH), London, United Kingdom, between 1972 and 1996. Outcome was compared with that of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocytic leukemia (B-CLL) treated at SBH during the same period. Patients and Methods: One hundred twenty-six patients with newly diagnosed IMC were identified. Patients were subclassified (using the Kiel classification) as having lymphoplasmacytoid (n =92), lymphoplasmacytic (n = 24), polymorphous (n = 9), or undetermined (n = 1) IMC. Six patients (5%) had stage I to IIE disease; the rest had advanced disease. Treatment was given according to disease stage. Seven patients were managed expectantly. Results: Eighty-two (69%) of 119 patients responded to treatment, but complete remission was seen in only 15 (13%) of 119. Treatment failed in 29 (24%) of 119 patients. There were three treatment-related deaths; five patients were not assessable for response. When survival of patients with IMC was compared with that of patients with B-CLL/SLL, a significant difference was found (P < .01); this difference was maintained when only patients in whom the diagnosis was based on lymph node biopsy were considered (P = .01). A comparison of the three IMC subgroups showed that there was a trend (P = .06) toward a difference between B-CLL/SLL and the lymphoplasmacytoid subtype. Conclusion: Patients diagnosed with IMC are generally older and present with advanced disease. Conventional therapies usually result in incomplete responses of short duration. Overall, these results support the proposed World Health Organization reclassification of IMC to include lymphoplasmacytoid lymphoma (Kiel classification) as a variant of B-CLL/SLL.

Original languageEnglish (US)
Pages (from-to)2847-2853
Number of pages7
JournalJournal of Clinical Oncology
Volume17
Issue number9
StatePublished - Sep 1999
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Waldenstrom Macroglobulinemia
Lymph Nodes
Biopsy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Papamichael, D., Norton, A. J., Foran, J. M., Mulatero, C., Mathews, J., Amess, J. A. L., ... Rohatiner, A. Z. S. (1999). Immunocytoma: A retrospective analysis from St Bartholomew's Hospital - 1972 to 1996. Journal of Clinical Oncology, 17(9), 2847-2853.

Immunocytoma : A retrospective analysis from St Bartholomew's Hospital - 1972 to 1996. / Papamichael, D.; Norton, A. J.; Foran, James M; Mulatero, C.; Mathews, J.; Amess, J. A L; Bradburn, M.; Lister, T. A.; Rohatiner, A. Z S.

In: Journal of Clinical Oncology, Vol. 17, No. 9, 09.1999, p. 2847-2853.

Research output: Contribution to journalArticle

Papamichael, D, Norton, AJ, Foran, JM, Mulatero, C, Mathews, J, Amess, JAL, Bradburn, M, Lister, TA & Rohatiner, AZS 1999, 'Immunocytoma: A retrospective analysis from St Bartholomew's Hospital - 1972 to 1996', Journal of Clinical Oncology, vol. 17, no. 9, pp. 2847-2853.
Papamichael D, Norton AJ, Foran JM, Mulatero C, Mathews J, Amess JAL et al. Immunocytoma: A retrospective analysis from St Bartholomew's Hospital - 1972 to 1996. Journal of Clinical Oncology. 1999 Sep;17(9):2847-2853.
Papamichael, D. ; Norton, A. J. ; Foran, James M ; Mulatero, C. ; Mathews, J. ; Amess, J. A L ; Bradburn, M. ; Lister, T. A. ; Rohatiner, A. Z S. / Immunocytoma : A retrospective analysis from St Bartholomew's Hospital - 1972 to 1996. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 9. pp. 2847-2853.
@article{b79867906cc1470292c2c07bb594aca8,
title = "Immunocytoma: A retrospective analysis from St Bartholomew's Hospital - 1972 to 1996",
abstract = "Purpose: To analyze the presentation features and outcome for patients with immunocytoma (IMC) managed at St Bartholomew's Hospital (SBH), London, United Kingdom, between 1972 and 1996. Outcome was compared with that of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocytic leukemia (B-CLL) treated at SBH during the same period. Patients and Methods: One hundred twenty-six patients with newly diagnosed IMC were identified. Patients were subclassified (using the Kiel classification) as having lymphoplasmacytoid (n =92), lymphoplasmacytic (n = 24), polymorphous (n = 9), or undetermined (n = 1) IMC. Six patients (5{\%}) had stage I to IIE disease; the rest had advanced disease. Treatment was given according to disease stage. Seven patients were managed expectantly. Results: Eighty-two (69{\%}) of 119 patients responded to treatment, but complete remission was seen in only 15 (13{\%}) of 119. Treatment failed in 29 (24{\%}) of 119 patients. There were three treatment-related deaths; five patients were not assessable for response. When survival of patients with IMC was compared with that of patients with B-CLL/SLL, a significant difference was found (P < .01); this difference was maintained when only patients in whom the diagnosis was based on lymph node biopsy were considered (P = .01). A comparison of the three IMC subgroups showed that there was a trend (P = .06) toward a difference between B-CLL/SLL and the lymphoplasmacytoid subtype. Conclusion: Patients diagnosed with IMC are generally older and present with advanced disease. Conventional therapies usually result in incomplete responses of short duration. Overall, these results support the proposed World Health Organization reclassification of IMC to include lymphoplasmacytoid lymphoma (Kiel classification) as a variant of B-CLL/SLL.",
author = "D. Papamichael and Norton, {A. J.} and Foran, {James M} and C. Mulatero and J. Mathews and Amess, {J. A L} and M. Bradburn and Lister, {T. A.} and Rohatiner, {A. Z S}",
year = "1999",
month = "9",
language = "English (US)",
volume = "17",
pages = "2847--2853",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Immunocytoma

T2 - A retrospective analysis from St Bartholomew's Hospital - 1972 to 1996

AU - Papamichael, D.

AU - Norton, A. J.

AU - Foran, James M

AU - Mulatero, C.

AU - Mathews, J.

AU - Amess, J. A L

AU - Bradburn, M.

AU - Lister, T. A.

AU - Rohatiner, A. Z S

PY - 1999/9

Y1 - 1999/9

N2 - Purpose: To analyze the presentation features and outcome for patients with immunocytoma (IMC) managed at St Bartholomew's Hospital (SBH), London, United Kingdom, between 1972 and 1996. Outcome was compared with that of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocytic leukemia (B-CLL) treated at SBH during the same period. Patients and Methods: One hundred twenty-six patients with newly diagnosed IMC were identified. Patients were subclassified (using the Kiel classification) as having lymphoplasmacytoid (n =92), lymphoplasmacytic (n = 24), polymorphous (n = 9), or undetermined (n = 1) IMC. Six patients (5%) had stage I to IIE disease; the rest had advanced disease. Treatment was given according to disease stage. Seven patients were managed expectantly. Results: Eighty-two (69%) of 119 patients responded to treatment, but complete remission was seen in only 15 (13%) of 119. Treatment failed in 29 (24%) of 119 patients. There were three treatment-related deaths; five patients were not assessable for response. When survival of patients with IMC was compared with that of patients with B-CLL/SLL, a significant difference was found (P < .01); this difference was maintained when only patients in whom the diagnosis was based on lymph node biopsy were considered (P = .01). A comparison of the three IMC subgroups showed that there was a trend (P = .06) toward a difference between B-CLL/SLL and the lymphoplasmacytoid subtype. Conclusion: Patients diagnosed with IMC are generally older and present with advanced disease. Conventional therapies usually result in incomplete responses of short duration. Overall, these results support the proposed World Health Organization reclassification of IMC to include lymphoplasmacytoid lymphoma (Kiel classification) as a variant of B-CLL/SLL.

AB - Purpose: To analyze the presentation features and outcome for patients with immunocytoma (IMC) managed at St Bartholomew's Hospital (SBH), London, United Kingdom, between 1972 and 1996. Outcome was compared with that of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocytic leukemia (B-CLL) treated at SBH during the same period. Patients and Methods: One hundred twenty-six patients with newly diagnosed IMC were identified. Patients were subclassified (using the Kiel classification) as having lymphoplasmacytoid (n =92), lymphoplasmacytic (n = 24), polymorphous (n = 9), or undetermined (n = 1) IMC. Six patients (5%) had stage I to IIE disease; the rest had advanced disease. Treatment was given according to disease stage. Seven patients were managed expectantly. Results: Eighty-two (69%) of 119 patients responded to treatment, but complete remission was seen in only 15 (13%) of 119. Treatment failed in 29 (24%) of 119 patients. There were three treatment-related deaths; five patients were not assessable for response. When survival of patients with IMC was compared with that of patients with B-CLL/SLL, a significant difference was found (P < .01); this difference was maintained when only patients in whom the diagnosis was based on lymph node biopsy were considered (P = .01). A comparison of the three IMC subgroups showed that there was a trend (P = .06) toward a difference between B-CLL/SLL and the lymphoplasmacytoid subtype. Conclusion: Patients diagnosed with IMC are generally older and present with advanced disease. Conventional therapies usually result in incomplete responses of short duration. Overall, these results support the proposed World Health Organization reclassification of IMC to include lymphoplasmacytoid lymphoma (Kiel classification) as a variant of B-CLL/SLL.

UR - http://www.scopus.com/inward/record.url?scp=0032857343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032857343&partnerID=8YFLogxK

M3 - Article

C2 - 10561361

AN - SCOPUS:0032857343

VL - 17

SP - 2847

EP - 2853

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -